The substantia nigra and ventral tegmental dopaminergic neurons from development to degeneration

Journal of Chemical Neuroanatomy

Volumn 76, Issue , 2016, Pages 98-107

  Fu, YuHong ^a,b   Paxinos, George ^a,b   Watson, Charles ^a   Halliday, Glenda M ^a,b  

^a NEUROSCIENCE RESEARCH AUSTRALIA   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Cytoarchitecture; Dopaminergic neurons; Parkinson's disease; Quantification; Substantia nigra; Ventral tegmental area

Indexed keywords

CALCIUM; TRANSCRIPTION FACTOR;

AGING; ARTICLE; BRAIN SIZE; CELL HETEROGENEITY; CELL SURVIVAL; CONNECTOME; DISEASE PREDISPOSITION; DOPAMINERGIC NERVE CELL; HUMAN; MOUSE; NERVE CELL DIFFERENTIATION; NERVE DEGENERATION; NEUROANATOMY; NEUROBIOLOGY; NEUROMERE; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUBSTANTIA NIGRA; VENTRAL TEGMENTUM;

EID: 84957702114     PISSN: 08910618     EISSN: 18736300     Source Type: Journal    
DOI: 10.1016/j.jchemneu.2016.02.001     Document Type: Article

References (143)

1. Alvarez-Fischer, D., Fuchs, J., Castagner, F., Stettler, O., Massiani-Beaudoin, O., et al. Engrailed protects mouse midbrain dopaminergic neurons against mitochondrial complex I insults. Nat. Neurosci. 14 (2011), 1260–1266, 10.1038/nn.2916.
2. Ang, S.L., Transcriptional control of midbrain dopaminergic neuron development. Development 133 (2006), 3499–3506, 10.1242/dev.02501.
3. Anglade, P., Vyas, S., Hirsch, E.C., Agid, Y., Apoptosis in dopaminergic neurons of the human substantia nigra during normal aging. Histol. Histopathol. 12 (1997), 603–610.
4. Aubert, I., Brana, C., Pellevoisin, C., Giros, B., Caille, I., et al. Molecular anatomy of the development of the human substantia nigra. J. Comp. Neurol. 379 (1997), 72–87.
5. Aumann, T.D., Egan, K., Lim, J., Boon, W.C., Bye, C.R., et al. Neuronal activity regulates expression of tyrosine hydroxylase in adult mouse substantia nigra pars compacta neurons. J. Neurochem. 116 (2011), 646–658, 10.1111/j.1471-4159.2010.07151.x.
6. Baker, H., Joh, T.H., Reis, D.J., Genetic control of number of midbrain dopaminergic neurons in inbred strains of mice: relationship to size and neuronal density of the striatum. Proc. Natl. Acad. Sci. U. S. A. 77 (1980), 4369–4373.
7. Bayer, S.A., Wills, K.V., Triarhou, L.C., Ghetti, B., Time of neuron origin and gradients of neurogenesis in midbrain dopaminergic neurons in the mouse. Exp. Brain Res. 105 (1995), 191–199.
8. Bender, A., Schwarzkopf, R.M., Mcmillan, A., Krishnan, K.J., Rieder, G., et al. Dopaminergic midbrain neurons are the prime target for mitochondrial DNA deletions. J. Neurol. 255 (2008), 1231–1235, 10.1007/s00415-008-0892-9.
9. Bergman, O., Hakansson, A., Westberg, L., Belin, A.C., Sydow, O., et al. Do polymorphisms in transcription factors LMX1A and LMX1B influence the risk for Parkinson's disease?. J. Neural Transm. 116 (2009), 333–338, 10.1007/s00702-009-0187-z.
10. Bergman, O., Hakansson, A., Westberg, L., Nordenstrom, K., Carmine Belin, A., et al. PITX3 polymorphism is associated with early onset Parkinson's disease. Neurobiol. Aging 31 (2010), 114–117, 10.1016/j.neurobiolaging.2008.03.008.
11. Besnard, V., Wert, S.E., Hull, W.M., Whitsett, J.A., Immunohistochemical localization of Foxa1 and Foxa2 in mouse embryos and adult tissues. Gene Expr. Patterns 5 (2004), 193–208, 10.1016/j.modgep.2004.08.006.
12. Björklund, A., Dunnett, S.B., Dopamine neuron systems in the brain: an update. Trends Neurosci. 30 (2007), 194–202, 10.1016/j.tins.2007.03.006.
13. Blaess, S., Ang, S.L., Genetic control of midbrain dopaminergic neuron development. Wiley Interdiscip. Rev. Dev. Biol. 4 (2015), 113–134, 10.1002/wdev.169.
14. Block, F., Dihne, M., Loos, M., Inflammation in areas of remote changes following focal brain lesion. Prog. Neurobiol. 75 (2005), 342–365, 10.1016/j.pneurobio.2005.03.004.
15. Bolam, J.P., Pissadaki, E.K., Living on the edge with too many mouths to feed: why dopamine neurons die. Mov. Disord. 27 (2012), 1478–1483, 10.1002/mds.25135.
16. Braak, H., Del Tredici, K., Poor and protracted myelination as a contributory factor to neurodegenerative disorders. Neurobiol. Aging 25 (2004), 19–23.
17. Braak, H., Ghebremedhin, E., Rub, U., Bratzke, H., Del Tredici, K., Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res. 318 (2004), 121–134, 10.1007/s00441-004-0956-9.
18. Braak, H., Thal, D.R., Ghebremedhin, E., Del Tredici, K., Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J. Neuropathol. Exp. Neurol. 70 (2011), 960–969, 10.1097/NEN.0b013e318232a379.
19. Brichta, L., Greengard, P., Molecular determinants of selective dopaminergic vulnerability in Parkinson's disease: an update. Front. Neuroanat., 8, 2014, 152, 10.3389/fnana.2014.00152.
20. Burke, W.J., Kumar, V.B., Pandey, N., Panneton, W.M., Gan, Q., et al. Aggregation of alpha-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine. Acta Neuropathol. 115 (2008), 193–203, 10.1007/s00401-007-0303-9.
21. Cabello, C.R., Thune, J.J., Pakkenberg, H., Pakkenberg, B., Ageing of substantia nigra in humans: cell loss may be compensated by hypertrophy. Neuropathol. Appl. Neurobiol. 28 (2002), 283–291.
22. Castellanos, G., Fernandez-Seara, M.A., Lorenzo-Betancor, O., Ortega-Cubero, S., Puigvert, M., et al. Automated neuromelanin imaging as a diagnostic biomarker for Parkinson's disease. Mov. Disord., 2015, 10.1002/mds.26201.
23. Celada, P., Paladini, C.A., Tepper, J.M., GABAergic control of rat substantia nigra dopaminergic neurons: role of globus pallidus and substantia nigra pars reticulata. Neuroscience 89 (1999), 813–825.
24. Chan, C.S., Guzman, J.N., Ilijic, E., Mercer, J.N., Rick, C., et al. ‘Rejuvenation’ protects neurons in mouse models of Parkinson's disease. Nature 447 (2007), 1081–1086, 10.1038/nature05865.
25. Chu, Y., Kompoliti, K., Cochran, E.J., Mufson, E.J., Kordower, J.H., Age-related decreases in Nurr1 immunoreactivity in the human substantia nigra. J. Comp. Neurol. 450 (2002), 203–214, 10.1002/cne.10261.
26. Chu, Y., Le, W., Kompoliti, K., Jankovic, J., Mufson, E.J., et al. Nurr1 in Parkinson's disease and related disorders. J. Comp. Neurol. 494 (2006), 495–514, 10.1002/cne.20828.
27. Collier, T.J., Kanaan, N.M., Kordower, J.H., Ageing as a primary risk factor for Parkinson's disease: evidence from studies of non-human primates. Nat. Rev. Neurosci. 12 (2011), 359–366, 10.1038/nrn3039.
28. Damier, P., Hirsch, E.C., Agid, Y., Graybiel, A.M., The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain 122:Pt. 8 (1999), 1437–1448.
29. Davie, C.A., A review of Parkinson's disease. Br. Med. Bull. 86 (2008), 109–127, 10.1093/bmb/ldn013.
30. Decressac, M., Volakakis, N., Bjorklund, A., Perlmann, T., NURR1 in Parkinson disease—from pathogenesis to therapeutic potential. Nat. Rev. Neurol. 9 (2013), 629–636, 10.1038/nrneurol.2013.209.
31. Di Giovanni, G., Di Matteo, V., Esposito, E., Birth, life and death of dopaminergic neurons in the substantia nigra. J. Neural Transm. Suppl., 2009 1 p preceeding table of contents.
32. Di Salvio, M., Di Giovannantonio, L.G., Acampora, D., Prosperi, R., Omodei, D., et al. Otx2 controls neuron subtype identity in ventral tegmental area and antagonizes vulnerability to MPTP. Nat. Neurosci. 13 (2010), 1481–1488, 10.1038/nn.2661.
33. Di Salvio, M., Di Giovannantonio, L.G., Omodei, D., Acampora, D., Simeone, A., Otx2 expression is restricted to dopaminergic neurons of the ventral tegmental area in the adult brain. Int. J. Dev. Biol. 54 (2010), 939–945, 10.1387/ijdb.092974ms.
34. Domanskyi, A., Alter, H., Vogt, M.A., Gass, P., Vinnikov, I.A., Transcription factors Foxa1 and Foxa2 are required for adult dopamine neurons maintenance. Front. Cell. Neurosci., 8, 2014, 275, 10.3389/fncel.2014.00275.
35. Doucet-Beaupré, H., Lévesque, M., The role of developmental transcription factors in adult midbrain dopaminergic neurons. OA Neurosci., 2013, 1.
36. Dragicevic, E., Poetschke, C., Duda, J., Schlaudraff, F., Lammel, S., et al. Cav1.3 channels control D2-autoreceptor responses via NCS-1 in substantia nigra dopamine neurons. Brain 137 (2014), 2287–2302, 10.1093/brain/awu131.
37. Dragicevic, E., Schiemann, J., Liss, B., Dopamine midbrain neurons in health and Parkinson's disease: emerging roles of voltage-gated calcium channels and ATP-sensitive potassium channels. Neuroscience 284 (2015), 798–814, 10.1016/j.neuroscience.2014.10.037.
38. Duan, D., Fu, Y., Paxinos, G., Watson, C., Spatiotemporal expression patterns of Pax6 in the brain of embryonic, newborn, and adult mice. Brain Struct. Funct. 218 (2013), 353–372, 10.1007/s00429-012-0397-2.
39. Dubois, B., Feldman, H.H., Jacova, C., Hampel, H., Molinuevo, J.L., et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol. 13 (2014), 614–629, 10.1016/S1474-4422(14) 70090-0.
40. Esteves, M., Cristovao, A.C., Saraiva, T., Rocha, S.M., Baltazar, G., et al. Retinoic acid-loaded polymeric nanoparticles induce neuroprotection in a mouse model for Parkinson's disease. Front. Aging Neurosci., 7, 2015, 20, 10.3389/fnagi.2015.00020.
41. Everts, H.B., Berdanier, C.D., Regulation of mitochondrial gene expression by retinoids. IUBMB Life 54 (2002), 45–49, 10.1080/15216540214316.
42. Fearnley, J.M., Lees, A.J., Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 114:Pt. 5 (1991), 2283–2301.
43. Fedorow, H., Tribl, F., Halliday, G., Gerlach, M., Riederer, P., et al. Neuromelanin in human dopamine neurons: comparison with peripheral melanins and relevance to Parkinson's disease. Prog. Neurobiol. 75 (2005), 109–124, 10.1016/j.pneurobio.2005.02.001.
44. Ferri, A.L., Lin, W., Mavromatakis, Y.E., Wang, J.C., Sasaki, H., et al. Foxa1 and Foxa2 regulate multiple phases of midbrain dopaminergic neuron development in a dosage-dependent manner. Development 134 (2007), 2761–2769, 10.1242/dev.000141.
45. Ford, C.P., The role of D2-autoreceptors in regulating dopamine neuron activity and transmission. Neuroscience 282C (2014), 13–22, 10.1016/j.neuroscience.2014.01.025.
46. Fu, Y., Yuan, Y., Halliday, G., Rusznak, Z., Watson, C., et al. A cytoarchitectonic and chemoarchitectonic analysis of the dopamine cell groups in the substantia nigra, ventral tegmental area, and retrorubral field in the mouse. Brain Struct. Funct. 217 (2012), 591–612, 10.1007/s00429-011-0349-2.
47. Fuchs, J., Mueller, J.C., Lichtner, P., Schulte, C., Munz, M., et al. The transcription factor PITX3 is associated with sporadic Parkinson's disease. Neurobiol. Aging 30 (2009), 731–738, 10.1016/j.neurobiolaging.2007.08.014.
48. Gantz, S.C., Bunzow, J.R., Williams, J.T., Spontaneous inhibitory synaptic currents mediated by a G protein-coupled receptor. Neuron 78 (2013), 807–812, 10.1016/j.neuron.2013.04.013.
49. German, D.C., Nelson, E.L., Liang, C.L., Speciale, S.G., Sinton, C.M., et al. The neurotoxin MPTP causes degeneration of specific nucleus A8, A9 and A10 dopaminergic neurons in the mouse. Neurodegeneration 5 (1996), 299–312.
50. Glaab, E., Schneider, R., Comparative pathway and network analysis of brain transcriptome changes during adult aging and in Parkinson's disease. Neurobiol. Dis. 74 (2015), 1–13, 10.1016/j.nbd.2014.11.002.
51. Goldstein, D.S., Sullivan, P., Holmes, C., Kopin, I.J., Sharabi, Y., et al. Decreased vesicular storage and aldehyde dehydrogenase activity in multiple system atrophy. Parkinsonism Relat. Disord. 21 (2015), 567–572, 10.1016/j.parkreldis.2015.03.006.
52. Goldstein, D.S., Sullivan, P., Holmes, C., Miller, G.W., Alter, S., et al. Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson's disease. J. Neurochem. 126 (2013), 591–603, 10.1111/jnc.12345.
53. Grünblatt, E., Zehetmayer, S., Jacob, C.P., Müller, T., Jost, W.H., et al. Pilot study: peripheral biomarkers for diagnosing sporadic Parkinson's disease. J. Neural Transm. 117 (2010), 1387–1393, 10.1007/s00702-010-0509-1.
54. Hall, F.S., Itokawa, K., Schmitt, A., Moessner, R., Sora, I., et al. Decreased vesicular monoamine transporter 2 (VMAT2) and dopamine transporter (DAT) function in knockout mice affects aging of dopaminergic systems. Neuropharmacology 76:Pt. A (2014), 146–155, 10.1016/j.neuropharm.2013.07.031.
55. Halliday, G.M., Tork, I., Comparative anatomy of the ventromedial mesencephalic tegmentum in the rat, cat, monkey and human. J. Comp. Neurol. 252 (1986), 423–445, 10.1002/cne.902520402.
56. Halliday, G.M., Mcritchie, D.A., Cartwright, H., Pamphlett, R., Hely, M.A., et al. Midbrain neuropathology in idiopathic Parkinson's disease and diffuse Lewy body disease. J. Clin. Neurosci. 3 (1996), 52–60.
57. Hardman, C.D., Mcritchie, D.A., Halliday, G.M., Cartwright, H.R., Morris, J.G., Substantia nigra pars reticulata neurons in Parkinson's disease. Neurodegeneration 5 (1996), 49–55.
58. Hardman, C.D., Henderson, J.M., Finkelstein, D.I., Horne, M.K., Paxinos, G., et al. Comparison of the basal ganglia in rats, marmosets, macaques, baboons, and humans: volume and neuronal number for the output internal relay, and striatal modulating nuclei. J. Comp. Neurol. 445 (2002), 238–255.
59. Haubenberger, D., Reinthaler, E., Mueller, J.C., Pirker, W., Katzenschlager, R., et al. Association of transcription factor polymorphisms PITX3 and EN1 with Parkinson's disease. Neurobiol. Aging 32 (2011), 302–307, 10.1016/j.neurobiolaging.2009.02.015.
60. Hebsgaard, J.B., Nelander, J., Sabelstrom, H., Jonsson, M.E., Stott, S., et al. Dopamine neuron precursors within the developing human mesencephalon show radial glial characteristics. Glia 57 (2009), 1648–1658, 10.1002/glia.20877.
61. Hegarty, S.V., Sullivan, A.M., O'keeffe, G.W., Midbrain dopaminergic neurons: a review of the molecular circuitry that regulates their development. Dev. Biol. 379 (2013), 123–138, 10.1016/j.ydbio.2013.04.014.
62. Hirsch, E., Graybiel, A.M., Agid, Y.A., Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 334 (1988), 345–348, 10.1038/334345a0.
63. Hornykiewicz, O., The discovery of dopamine deficiency in the Parkinsonian brain. J. Neural Transm. Suppl., 2006, 9–15.
64. Hurley, M.J., Brandon, B., Gentleman, S.M., Dexter, D.T., Parkinson's disease is associated with altered expression of CaV1 channels and calcium-binding proteins. Brain 136 (2013), 2077–2097, 10.1093/brain/awt134.
65. Hwang, D.Y., Ardayfio, P., Kang, U.J., Semina, E.V., Kim, K.S., Selective loss of dopaminergic neurons in the substantia nigra of Pitx3-deficient aphakia mice. Brain Res. Mol. Brain Res. 114 (2003), 123–131.
66. Ilango, A., Kesner, A.J., Keller, K.L., Stuber, G.D., Bonci, A., et al. Similar roles of substantia nigra and ventral tegmental dopamine neurons in reward and aversion. J. Neurosci. 34 (2014), 817–822, 10.1523/JNEUROSCI.1703-13.2014.
67. Jacobs, F.M., Smits, S.M., Noorlander, C.W., Von Oerthel, L., Van Der Linden, A.J., et al. Retinoic acid counteracts developmental defects in the substantia nigra caused by Pitx3 deficiency. Development 134 (2007), 2673–2684, 10.1242/dev.02865.
68. Jang, A., Lee, H.J., Suk, J.E., Jung, J.W., Kim, K.P., et al. Non-classical exocytosis of alpha-synuclein is sensitive to folding states and promoted under stress conditions. J. Neurochem. 113 (2010), 1263–1274, 10.1111/j.1471-4159.2010.06695.x.
69. Jang, J.Y., Jang, M., Kim, S.H., Um, K.B., Kang, Y.K., et al. Regulation of dopaminergic neuron firing by heterogeneous dopamine autoreceptors in the substantia nigra pars compacta. J. Neurochem. 116 (2011), 966–974, 10.1111/j.1471-4159.2010.07107.x.
70. Kadkhodaei, B., Ito, T., Joodmardi, E., Mattsson, B., Rouillard, C., et al. Nurr1 is required for maintenance of maturing and adult midbrain dopamine neurons. J. Neurosci. 29 (2009), 15923–15932, 10.1523/JNEUROSCI.3910-09.2009.
71. Khaliq, Z.M., Bean, B.P., Pacemaking in dopaminergic ventral tegmental area neurons: depolarizing drive from background and voltage-dependent sodium conductances. J. Neurosci. 30 (2010), 7401–7413, 10.1523/JNEUROSCI.0143-10.2010.
72. Kitamura, M., Ishikawa, Y., Moreno-Manzano, V., Xu, Q., Konta, T., et al. Intervention by retinoic acid in oxidative stress-induced apoptosis. Nephrol. Dial. Transplant. 17:Suppl. 9 (2002), 84–87.
73. Kittappa, R., Chang, W.W., Awatramani, R.B., Mckay, R.D., The foxa2 gene controls the birth and spontaneous degeneration of dopamine neurons in old age. PLoS Biol., 5, 2007, e325, 10.1371/journal.pbio.0050325.
74. Ko, H.A., Chen, S.Y., Chen, H.Y., Hao, H.J., Liu, F.C., Cell type-selective expression of the zinc finger-containing gene Nolz-1/Zfp503 in the developing mouse striatum. Neurosci. Lett. 548 (2013), 44–49, 10.1016/j.neulet.2013.05.020.
75. Laguna, A., Schintu, N., Nobre, A., Alvarsson, A., Volakakis, N., et al. Dopaminergic control of autophagic-lysosomal function implicates Lmx1b in Parkinson's disease. Nat. Neurosci., 2015, 10.1038/nn.4004.
76. Lammel, S., Steinberg, E.E., Foldy, C., Wall, N.R., Beier, K., et al. Diversity of transgenic mouse models for selective targeting of midbrain dopamine neurons. Neuron 85 (2015), 429–438, 10.1016/j.neuron.2014.12.036.
77. Lee, H.J., Cho, E.D., Lee, K.W., Kim, J.H., Cho, S.G., et al. Autophagic failure promotes the exocytosis and intercellular transfer of alpha-synuclein. Exp. Mol. Med., 45, 2013, e22, 10.1038/emm.2013.45.
78. Lee, H.J., Bae, E.J., Lee, S.J., Extracellular alpha-synuclein—a novel and crucial factor in Lewy body diseases. Nat. Rev. Neurol. 10 (2014), 92–98, 10.1038/nrneurol.2013.275.
79. Lein, E.S., Hawrylycz, M.J., Ao, N., Ayres, M., Bensinger, A., et al. Genome-wide atlas of gene expression in the adult mouse brain. Nature 445 (2007), 168–176, 10.1038/nature05453.
80. Lesnick, T.G., Papapetropoulos, S., Mash, D.C., Ffrench-Mullen, J., Shehadeh, L., et al. A genomic pathway approach to a complex disease: axon guidance and Parkinson disease. PLoS Genet., 3, 2007, e98, 10.1371/journal.pgen.0030098.
81. Lin, L., Lesnick, T.G., Maraganore, D.M., Isacson, O., Axon guidance and synaptic maintenance: preclinical markers for neurodegenerative disease and therapeutics. Trends Neurosci. 32 (2009), 142–149, 10.1016/j.tins.2008.11.006.
82. Liu, G., Yu, J., Ding, J., Xie, C., Sun, L., et al. Aldehyde dehydrogenase 1 defines and protects a nigrostriatal dopaminergic neuron subpopulation. J. Clin. Investig. 124 (2014), 3032–3046, 10.1172/JCI72176.
83. Ma, S.Y., Röyttä, M., Rinne, J.O., Collan, Y., Rinne, U.K., Single section and disector counts in evaluating neuronal loss from the substantia nigra in patients with Parkinsonös disease. Neuropathol. Appl. Neurobiol. 21 (1995), 341–343.
84. Ma, S.Y., Röytt, M., Collan, Y., Rinne, J.O., Unbiased morphometrical measurements show loss of pigmented nigral neurones with ageing. Neuropathol. Appl. Neurobiol. 25 (1999), 394–399.
85. Maingay, M., Romero-Ramos, M., Carta, M., Kirik, D., Ventral tegmental area dopamine neurons are resistant to human mutant alpha-synuclein overexpression. Neurobiol. Dis. 23 (2006), 522–532, 10.1016/j.nbd.2006.04.007.
86. Marchitti, S.A., Deitrich, R.A., Vasiliou, V., Neurotoxicity and metabolism of the catecholamine-derived 3,4-dihydroxyphenylacetaldehyde and 3,4-dihydroxyphenylglycolaldehyde: the role of aldehyde dehydrogenase. Pharmacol. Rev. 59 (2007), 125–150, 10.1124/pr.59.2.1.
87. Marin, F., Herrero, M.T., Vyas, S., Puelles, L., Ontogeny of tyrosine hydroxylase mRNA expression in mid- and forebrain: neuromeric pattern and novel positive regions. Dev. Dyn. 234 (2005), 709–717, 10.1002/dvdy.20467.
88. Martinez, S., The isthmic organizer and brain regionalization. Int. J. Dev. Biol. 45 (2001), 367–371.
89. Matsuda, W., Furuta, T., Nakamura, K.C., Hioki, H., Fujiyama, F., et al. Single nigrostriatal dopaminergic neurons form widely spread and highly dense axonal arborizations in the neostriatum. J. Neurosci. 29 (2009), 444–453, 10.1523/JNEUROSCI.4029-08.2009.
90. McRitchie, D.A., Halliday, G.M., Cartwright, H., Quantitative analysis of the variability of substantia nigra pigmented cell clusters in the human. Neuroscience 68 (1995), 539–551.
91. McRitchie, D.A., Hardman, C.D., Halliday, G.M., Cytoarchitectural distribution of calcium binding proteins in midbrain dopaminergic regions of rats and humans. J. Comp. Neurol. 364 (1996), 121–150, 10.1002/(SICI)1096-9861(19960101)364:1<121::AID-CNE11>3.0.CO;2-1.
92. McRitchie, D.A., Cartwright, H.R., Halliday, G.M., Specific A10 dopaminergic nuclei in the midbrain degenerate in Parkinson's disease. Exp. Neurol. 144 (1997), 202–213, 10.1006/exnr.1997.6418.
93. Mencacci, N.E., Isaias, I.U., Reich, M.M., Ganos, C., Plagnol, V., et al. Parkinson's disease in GTP cyclohydrolase 1 mutation carriers. Brain 137 (2014), 2480–2492, 10.1093/brain/awu179.
94. Nelson, E.L., Liang, C.L., Sinton, C.M., German, D.C., Midbrain dopaminergic neurons in the mouse: computer-assisted mapping. J. Comp. Neurol. 369 (1996), 361–371, 10.1002/(SICI)1096-9861(19960603)369:3<361::AID-CNE3>3.0.CO;2-3.
95. Omodei, D., Acampora, D., Mancuso, P., Prakash, N., Di Giovannantonio, L.G., et al. Anterior-posterior graded response to Otx2 controls proliferation and differentiation of dopaminergic progenitors in the ventral mesencephalon. Development 135 (2008), 3459–3470, 10.1242/dev.027003.
96. Osborne, P.B., Halliday, G.M., Cooper, H.M., Keast, J.R., Localization of immunoreactivity for deleted in colorectal cancer (DCC), the receptor for the guidance factor netrin-1, in ventral tier dopamine projection pathways in adult rodents. Neuroscience 131 (2005), 671–681, 10.1016/j.neuroscience.2004.11.043.
97. Pan, P.Y., Ryan, T.A., Calbindin controls release probability in ventral tegmental area dopamine neurons. Nat. Neurosci. 15 (2012), 813–815, 10.1038/nn.3099.
98. Panman, L., Papathanou, M., Laguna, A., Oosterveen, T., Volakakis, N., et al. Sox6 and Otx2 control the specification of substantia nigra and ventral tegmental area dopamine neurons. Cell Rep. 8 (2014), 1018–1025, 10.1016/j.celrep.2014.07.016.
99. Panneton, W.M., Kumar, V.B., Gan, Q., Burke, W.J., Galvin, J.E., The neurotoxicity of DOPAL: behavioral and stereological evidence for its role in Parkinson disease pathogenesis. PLoS One, 5, 2010, e15251, 10.1371/journal.pone.0015251.
100. Parkkinen, L., O'sullivan, S.S., Collins, C., Petrie, A., Holton, J.L., et al. Disentangling the relationship between lewy bodies and nigral neuronal loss in Parkinson's disease. J. Parkinson's Dis. 1 (2011), 277–286, 10.3233/JPD-2011-11046.
101. Peng, C., Aron, L., Klein, R., Li, M., Wurst, W., et al. Pitx3 is a critical mediator of GDNF-induced BDNF expression in nigrostriatal dopaminergic neurons. J. Neurosci. 31 (2011), 12802–12815, 10.1523/JNEUROSCI.0898-11.2011.
102. Perlmann, T., Retinoid metabolism: a balancing act. Nat. Genet. 31 (2002), 7–8, 10.1038/ng877.
103. Prensa, L., Parent, A., The nigrostriatal pathway in the rat: a single-axon study of the relationship between dorsal and ventral tier nigral neurons and the striosome/matrix striatal compartments. J. Neurosci. 21 (2001), 7247–7260.
104. Puelles, L., Martinez-De-La-Torre, M., Paxinos, G., Watson, C., Martinez, S., The Chick Brain in Stereotaxic Coordinations. 2007, Elsevier Academic Press, San Diego.
105. Puelles, L., Harrison, M., Paxinos, G., Watson, C., A developmental ontology for the mammalian brain based on the prosomeric model. Trends Neurosci. 36 (2013), 570–578, 10.1016/j.tins.2013.06.004.
106. Quiat, D., Voelker, K.A., Pei, J., Grishin, N.V., Grange, R.W., et al. Concerted regulation of myofiber-specific gene expression and muscle performance by the transcriptional repressor Sox6. Proc. Natl. Acad. Sci. U. S. A. 108 (2011), 10196–10201, 10.1073/pnas.1107413108.
107. Reeve, A., Simcox, E., Turnbull, D., Ageing and Parkinson's disease: why is advancing age the biggest risk factor?. Ageing Res. Rev. 14 (2014), 19–30, 10.1016/j.arr.2014.01.004.
108. Reimao, S., Pita Lobo, P., Neutel, D., Guedes, L.C., Coelho, M., et al. Substantia nigra neuromelanin-MR imaging differentiates essential tremor from Parkinson's disease. Mov. Disord., 2015, 10.1002/mds.26182.
109. Reyes, S., Fu, Y., Double, K., Thompson, L., Kirik, D., et al. GIRK2 expression in dopamine neurons of the substantia nigra and ventral tegmental area. J. Comp. Neurol. 520 (2012), 2591–2607, 10.1002/cne.23051.
110. Reyes, S., Cottam, V., Kirik, D., Double, K.L., Halliday, G.M., Variability in neuronal expression of dopamine receptors and transporters in the substantia nigra. Mov. Disord. 28 (2013), 1351–1359, 10.1002/mds.25493.
111. Reyes, S., Fu, Y., Double, K.L., Cottam, V., Thompson, L.H., et al. Trophic factors differentiate dopamine neurons vulnerable to Parkinson's disease. Neurobiol. Aging 34 (2013), 873–886, 10.1016/j.neurobiolaging.2012.07.019.
112. Rudow, G., O'brien, R., Savonenko, A.V., Resnick, S.M., Zonderman, A.B., et al. Morphometry of the human substantia nigra in ageing and Parkinson's disease. Acta Neuropathol. 115 (2008), 461–470, 10.1007/s00401-008-0352-8.
113. Salvatore, M.F., Pruett, B.S., Dichotomy of tyrosine hydroxylase and dopamine regulation between somatodendritic and terminal field areas of nigrostriatal and mesoaccumbens pathways. PLoS One, 7, 2012, e29867, 10.1371/journal.pone.0029867.
114. Sasaki, H., Hogan, B.L., HNF-3 beta as a regulator of floor plate development. Cell 76 (1994), 103–115.
115. Simeone, A., Di Salvio, M., Di Giovannantonio, L.G., Acampora, D., Omodei, D., et al. The role of otx2 in adult mesencephalic-diencephalic dopaminergic neurons. Mol. Neurobiol. 43 (2011), 107–113, 10.1007/s12035-010-8148-y.
116. Smeets, W.J., González, A., Catecholamine systems in the brain of vertebrates: new perspectives through a comparative approach. Brain Res. Brain Res. Rev. 33 (2000), 308–379.
117. Smidt, M.P., Burbach, J.P., How to make a mesodiencephalic dopaminergic neuron. Nat. Rev. Neurosci. 8 (2007), 21–32, 10.1038/nrn2039.
118. Smidt, M.P., Smits, S.M., Burbach, J.P., Molecular mechanisms underlying midbrain dopamine neuron development and function. Eur. J. Pharmacol. 480 (2003), 75–88.
119. Spatazza, J., Di Lullo, E., Joliot, A., Dupont, E., Moya, K.L., et al. Homeoprotein signaling in development, health, and disease: a shaking of dogmas offers challenges and promises from bench to bed. Pharmacol. Rev. 65 (2013), 90–104, 10.1124/pr.112.006577.
120. Stark, A.K., Pakkenberg, B., Histological changes of the dopaminergic nigrostriatal system in aging. Cell Tissue Res. 318 (2004), 81–92, 10.1007/s00441-004-0972-9.
121. Stott, S.R., Metzakopian, E., Lin, W., Kaestner, K.H., Hen, R., et al. Foxa1 and foxa2 are required for the maintenance of dopaminergic properties in ventral midbrain neurons at late embryonic stages. J. Neurosci. 33 (2013), 8022–8034, 10.1523/JNEUROSCI.4774-12.2013.
122. Subramaniam, S.R., Vergnes, L., Franich, N.R., Reue, K., Chesselet, M.F., Region specific mitochondrial impairment in mice with widespread overexpression of alpha-synuclein. Neurobiol. Dis. 70 (2014), 204–213, 10.1016/j.nbd.2014.06.017.
123. Sukhorukova, E.G., Alekseeva, O.S., Korzhevskii, D.E., Catecholaminergic neurons of mammalian brain and neuromelanin. Zh. Evol. Biokhim. Fiziol. 50 (2014), 336–342.
124. Surmeier, D.J., A lethal convergence of dopamine and calcium. Neuron 62 (2009), 163–164, 10.1016/j.neuron.2009.04.010.
125. Surmeier, D.J., Guzman, J.N., Sanchez-Padilla, J., Goldberg, J.A., What causes the death of dopaminergic neurons in Parkinson's disease?. Prog. Brain Res. 183 (2010), 59–77, 10.1016/S0079-6123(10) 83004-3.
126. Tabrez, S., Jabir, N.R., Shakil, S., Greig, N.H., Alam, Q., et al. A synopsis on the role of tyrosine hydroxylase in Parkinson's disease. CNS Neurol. Disord. Drug Targets 11 (2012), 395–409.
127. Takeda, A., Nyssen, O.P., Syed, A., Jansen, E., Bueno-De-Mesquita, B., et al. Vitamin A and carotenoids and the risk of Parkinson's disease: a systematic review and meta-analysis. Neuroepidemiology 42 (2014), 25–38, 10.1159/000355849.
128. Van Den Munckhof, P., Luk, K.C., Ste-Marie, L., Montgomery, J., Blanchet, P.J., et al. Pitx3 is required for motor activity and for survival of a subset of midbrain dopaminergic neurons. Development 130 (2003), 2535–2542.
129. Veenvliet, J.V., Smidt, M.P., Molecular mechanisms of dopaminergic subset specification: fundamental aspects and clinical perspectives. Cell Mol. Life Sci. 71 (2014), 4703–4727, 10.1007/s00018-014-1681-5.
130. Verina, T., Kiihl, S.F., Schneider, J.S., Guilarte, T.R., Manganese exposure induces microglia activation and dystrophy in the substantia nigra of non-human primates. Neurotoxicology 32 (2011), 215–226, 10.1016/j.neuro.2010.11.003.
131. Wallen, A., Zetterstrom, R.H., Solomin, L., Arvidsson, M., Olson, L., et al. Fate of mesencephalic AHD2-expressing dopamine progenitor cells in NURR1 mutant mice. Exp. Cell Res. 253 (1999), 737–746, 10.1006/excr.1999.4691.
132. Wang, Q., Chu, C.H., Qian, L., Chen, S.H., Wilson, B., et al. Substance P exacerbates dopaminergic neurodegeneration through neurokinin-1 receptor-independent activation of microglial NADPH oxidase. J. Neurosci. 34 (2014), 12490–12503, 10.1523/JNEUROSCI.2238-14.2014.
133. Watabe-Uchida, M., Zhu, L., Ogawa, S.K., Vamanrao, A., Uchida, N., Whole-brain mapping of direct inputs to midbrain dopamine neurons. Neuron 74 (2012), 858–873, 10.1016/j.neuron.2012.03.017.
134. Watson, C., The presumptive isthmic region in a mouse as defined by fgf8 expression. Brain Behav. Evol., 75, 2010, 315.
135. Windels, F., Kiyatkin, E.A., Dopamine action in the substantia nigra pars reticulata: iontophoretic studies in awake, unrestrained rats. Eur. J. Neurosci. 24 (2006), 1385–1394, 10.1111/j.1460-9568.2006.05015.x.
136. Winklhofer, K.F., Haass, C., Mitochondrial dysfunction in Parkinson's disease. Biochim. Biophys. Acta 1802 (2010), 29–44, 10.1016/j.bbadis.2009.08.013.
137. Yang, Y.X., Latchman, D.S., Nurr1 transcriptionally regulates the expression of alpha-synuclein. NeuroReport 19 (2008), 867–871, 10.1097/WNR.0b013e3282ffda48.
138. Zaborszky, L., Vadasz, C., The midbrain dopaminergic system: anatomy and genetic variation in dopamine neuron number of inbred mouse strains. Behav. Genet. 31 (2001), 47–59.
139. Zaltieri, M., Longhena, F., Pizzi, M., Missale, C., Spano, P., et al. Mitochondrial dysfunction and alpha-synuclein synaptic pathology in Parkinson's disease: who's on first?. Parkinson's Dis., 2015, 2015, 108029, 10.1155/2015/108029.
140. Zecca, L., Tampellini, D., Gerlach, M., Riederer, P., Fariello, R.G., et al. Substantia nigra neuromelanin: structure synthesis, and molecular behaviour. Mol. Pathol. 54 (2001), 414–418.
141. Zecca, L., Zucca, F.A., Costi, P., Tampellini, D., Gatti, A., et al. The neuromelanin of human substantia nigra: structure, synthesis and molecular behaviour. J. Neural Transm. Suppl., 2003, 145–155.
142. Zheng, K., Heydari, B., Simon, D.K., A common NURR1 polymorphism associated with Parkinson disease and diffuse Lewy body disease. Arch. Neurol. 60 (2003), 722–725, 10.1001/archneur.60.5.722.
143. Zhu, Y., Zhang, J., Zeng, Y., Overview of tyrosine hydroxylase in Parkinson's disease. CNS Neurol. Disord. Drug Targets 11 (2012), 350–358.